In this week's edition...
 
— PIPC Statement on GENEROUS Model, also known as “Most Favored Nation." View the statement here.
— Prasad and Makary Discuss Novel FDA Plausible Mechanism Pathway. Click here to read the NEJM publication.
— New PQA Patient Advisory Council Seeks Nominations. Individuals can submit their nominations via this form. Additional details are provided in a recent PQA blog.
— Draft HEMA Report: USC Schaeffer Makes Case Against Accepting Individual Harms to Improve Population Averages. View USC Schaeffer’s response to the draft report here.
— PCORI Discusses the Importance of Patient-Centered Comparative CER Research. Click here to read more.
— Health Affairs: PIPC Chairman Highlights PDAB Shortcomings. Click here to view the article. 
-- The Baltimore Sun: Maryland's Drug Affordability Board Has Been a Failure. View the opinion here. 
— PIPC Chairman Explains that the MFN is Exacting Too High a Price for Patients and People with Disabilities. Click here to read the statement.
— SFS Releases Survey Results Detailing Americans' Rejection of Foreign Drug Pricing Schemes. See details below.
— Reps. Cammack and Hern Introduce QALY Ban Bill. See details below.
— Opportunity: Sign an Open Letter Rejecting Use of QALYs and Similar Measures. See details below.
— Update on the Texas v. Kennedy Lawsuit. See details below.
— Emerging Threats in States for Use of Discriminatory Metrics. See details below.
— What Happens in Countries Using QALYs and Cost-Based Thresholds? See details below.
— ICER's QALY-Based Study Topics. See details below.
— Upcoming Events and Webinars. See details below.

The Partnership to Improve Patient Care (PIPC) has issued the following statement in response to the Trump administration's "GENEROUS" model. 

In this week's edition...
 
— Health Affairs: PIPC Chairman Highlights PDAB Shortcomings. Click here to view the article. 
— ICER Again Fails to Address Patient and Disability Concerns Related to its Biased Methodology. View PIPC’s Data Mine blog related to the methodology and protocol here.
-- The Baltimore Sun: Maryland's Drug Affordability Board Has Been a Failure. View the opinion here. 
— PIPC Response to Trump Administration’s Continued Push for MFN Pricing. Click here to view the statement.
— PharmaPhorum Discusses the Affordability of Medicines and Innovation. Click here to read the article.
— PIPC Chairman Explains that the MFN is Exacting Too High a Price for Patients and People with Disabilities. Click here to read the statement.
— SFS Releases Survey Results Detailing Americans' Rejection of Foreign Drug Pricing Schemes. See details below.
— Reps. Cammack and Hern Introduce QALY Ban Bill. See details below.
— Opportunity: Sign an Open Letter Rejecting Use of QALYs and Similar Measures. See details below.
— Update on the Texas v. Kennedy Lawsuit. See details below.
— Emerging Threats in States for Use of Discriminatory Metrics. See details below.
— What Happens in Countries Using QALYs and Cost-Based Thresholds? See details below.
— ICER's QALY-Based Study Topics. See details below.
— Upcoming Events and Webinars. See details below.